• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    G1 Therapeutics Inc (NQ: GTHX )

    3.565 +0.045 (+1.28%)
    Streaming Delayed Price Updated: 1:52 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 474,192
    Open 3.480
    Bid (Size) 3.560 (5)
    Ask (Size) 3.570 (2)
    Prev. Close 3.520
    Today's Range 3.470 - 3.645
    52wk Range 1.080 - 6.140
    Shares Outstanding 42,705,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
    While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. 
    Via InvestorPlace
    Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
    G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal. 
    Via InvestorPlace

    Performance

    YTD
    +14.63%
    +14.63%
    1 Month
    +33.52%
    +33.52%
    3 Month
    -16.71%
    -16.71%
    6 Month
    +3.33%
    +3.33%
    1 Year
    +40.35%
    +40.35%

    More News

    Read More
    Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
    Via InvestorPlace
    Exposures Product Safety
    Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    Analyst Ratings For G1 Therapeutics
    Via Benzinga
    Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
    Via Benzinga
    Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
    Via Benzinga
    Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
    Via Benzinga
    Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
    From G1 Therapeutics
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
    From G1 Therapeutics
    Via GlobeNewswire
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
    From G1 Therapeutics
    Via GlobeNewswire
    What's Going On With G1 Therapeutics Stock?
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
    From G1 Therapeutics
    Via GlobeNewswire
    G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
    From G1 Therapeutics
    Via GlobeNewswire
    Biotech Innovations Paving the Way in Breast Cancer Fight
    Via FinancialNewsMedia
    Topics Death
    Exposures Death Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.